Anti-tuberculosis drug-induced liver injury in Shanghai: Validation of Hy's law

Drug Safety

Volumn 37, Issue 1, 2014, Pages 43-51

  Shen, Xin ^a   Yuan, Zheng'an ^a   Mei, Jian ^a   Zhang, Zurong ^a   Guo, Juntao ^a   Wu, Zheyuan ^a   Wu, Jie ^a   Zhang, Haihua ^b   Pan, Jieping ^b   Huang, Wenming ^c   Gong, Huili ^c   Yuan, Dong ^a   Xiao, Ping ^a   Wang, Yanqin ^a   Shuai, Yi ^a   Lin, Senlin ^a   Pan, Qichao ^a   Zhou, Tong ^a,d   Watkins, Paul B ^e,f   Wu, Fan ^a  

^a SHANGHAI MUNICIPAL CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b Affiliated Nanhua Hospital of Nanhua University   (China)

^c Pudong Hospital   (China)

^d Gentris Corporation   (United States)

^e HAMNER INSTITUTES FOR HEALTH SCIENCES   (United States)

^f IL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; BILIRUBIN; ETHAMBUTOL; HEPATITIS B SURFACE ANTIGEN; ISONIAZID; LIVER PROTECTIVE AGENT; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; DRINKING BEHAVIOR; DRUG LEGISLATION; DRUG SAFETY; FEMALE; HEPATITIS B; HUMAN; HYPERTRANSAMINASEMIA; LIVER DISEASE; LIVER PROTECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SMOKING; TOXIC HEPATITIS; TUBERCULOSIS; TUBERCULOSIS CONTROL;

ADULT; AGED; ALANINE TRANSAMINASE; ANTITUBERCULAR AGENTS; CHINA; DRUG-INDUCED LIVER INJURY; FEMALE; HEPATITIS B, CHRONIC; HUMANS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PRODUCT SURVEILLANCE, POSTMARKETING; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TUBERCULOSIS;

EID: 84896883278     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-013-0119-6     Document Type: Article

References (19)

1. Senior JR. Alanine aminotransferase: a clinical and regulatory tool for detecting liver injury-past, present, and future. Clin Pharmacol Ther. 2012;92(3):332-9.
2. Guidance for industry. Drug-induced liver injury: premarketing clinical evaluation. 2009. Available from: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM174090.pdf
3. Andrade RJ, Lucena MI, Kaplowitz N, Garcia-Munoz B, Borraz Y, Pachkoria K, et al. Outcome of acute idiosyncratic druginduced liver injury: long-term follow-up in a hepatotoxicity registry. Hepatology. 2006;44(6):1581-8. (Pubitemid 44953663)
4. Bjornsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology. 2005;42(2):481-9. (Pubitemid 41061102)
5. Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology. 2008;135(6):1924-34, 34 e1-4.
6. Watkins PB, Desai M, Berkowitz SD, Peters G, Horsmans Y, Larrey D, et al. Evaluation of drug-induced serious hepatotoxicity (eDISH): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery. Drug Saf. 2011;34(3):243-52.
7. McClain CJ, Price S, Barve S, Devalarja R, Shedlofsky S. Acetaminophen hepatotoxicity: an update. Curr Gastroenterol Rep. 1999;1(1):42-9.
8. Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ, Dekhuijzen R. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol. 2008;23(2):192-202. (Pubitemid 351257678)
9. Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006;174(8):935-52. (Pubitemid 44564795)
10. Yew WW, Leung CC. Antituberculosis drugs and hepatotoxicity. Respirology. 2006;11(6):699-707. (Pubitemid 44581433)
11. WHO. Treatment of tuberculosis: guidelines for national programmes. Geneva: WHO; 2003.
12. Turner MO, Elwood RK. Severe hepatic complications of antituberculous therapy. Can J Infect Dis. 1999;10(2):167-9. (Pubitemid 29239050)
13. Tost JR, Vidal R, Cayla J, Diaz-Cabanela D, Jimenez A, Broquetas JM. Severe hepatotoxicity due to anti-tuberculosis drugs in Spain. Int J Tuberc Lung Dis. 2005;9(5):534-40. (Pubitemid 40646839)
14. MOH. Guidelines for implementing the national tuberculosis control program in China. MOH; 2008.
15. Lai RT, Wang H, Gui HL, Ye MZ, Dai WJ, Xiang XG, et al. Clinical and pathological features in 138 cases of drug-induced liver injury. Zhonghua Gan Zang Bing Za Zhi. 2012;20(3):185-9.
16. Wu JC, Lee SD, Yeh PF, Chan CY, Wang YJ, Huang YS, et al. Isoniazid-rifampin-induced hepatitis in hepatitis B carriers. Gastroenterology. 1990;98(2):502-4.
17. Wong WM, Wu PC, Yuen MF, Cheng CC, Yew WW, Wong PC, et al. Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology. 2000;31(1):201-6.
18. Lee BH, Koh WJ, Choi MS, Suh GY, Chung MP, Kim H, et al. Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy. Chest. 2005;127(4):1304-11. (Pubitemid 46224295)
19. Wang JY, Liu CH, Hu FC, Chang HC, Liu JL, Chen JM et al. Risk factors of hepatitis during anti-tuberculous treatment and implications of hepatitis virus load. J Infect 2011;62(6):448-55.